PharmaTimes - November 2017

Ahead of our Marketer of the Year awards ceremony in November, we thought we’d take a look at some of the most important tools available to modern pharma marketers.

Social media is increasingly important for all industries. Pharma might face an uphill battle to be heard among a sea of celebrities and breaking news — but as shown in this month’s cover feature (p34), with exclusive research conducted for PharmaTimes, companies are already starting to figure out what works best.

Of course, social media is just one channel among many that marketers can harness to get their message across, and these days marketing is really about multichannel strategies. That said, research shows that the European industry is falling behind in this area, so in The Secrets of Multichannel (p31) we ask how they can start to close the gap.

Other articles this month include a look at an exciting new gene therapy delivery technology (p28), an interview with Bayer’s new UK & Ireland CEO Lars Bruening (p39) and a focus on joint working in IBD Registry Industry Working Group (p20) — along with a Patient Files focusing on ulcerative colitis (p45).

November 2017 - magazine highlights

Greater good

Richard Gardner, British Society of Gastroenterology chief...

Patient Files: Ulcerative colitis

Charlotte Guinea talks about her experiences with this ‘in...

What science really means

Five years on from Pfizer selling Discovery Park, the site...

Age of discovery

Five years on from Pfizer selling Discovery Park, the site...

Delivering the goods

Biotech firm Nanogenics believes that its product LipTide...

The secrets of multichannel

Europe is lagging when it comes to multichannel engagement...

Exposing the true cost of care

Sue Thomas and Paul Midgley of Wilmington Healthcare explo...

Chain reaction

How can blockchain help the pharma supply chain?

Compliance in finance

What does the new Criminal Finance Act mean for pharma?

#pharma

An exclusive analysis conducted by Talkwalker for PharmaTi...